Answers are grounded in this paper and cite their sources.
Trametinib, an MEK inhibitor, may offer a new therapeutic option for patients with NF1-related GIST.
No takes yet. Share an insight, caveat, or question.
Fukuda et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: